Pharmaceutical Journal

• On 28 April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority introduced the most significant package of clinical trial reforms in over 20 years. • The legislative changes aim to accelerate the setup of low-risk trials and streamline the process for making modifications to existing studies. • These reforms matter because they are designed to provide patients with earlier access to innovative medicines by reducing regulatory bottlenecks.

• The Pharmaceutical Journal reported on several key healthcare developments, including progress toward a single national formulary and the potential introduction of a pharmacy performers list. • The publication highlighted a "stark lack of government response" regarding the valproate redress scheme, signaling ongoing frustration over compensation for affected individuals. • Efforts are underway to establish closer regulatory ties between the UK, India, and the United States to streamline pharmaceutical oversight.

• A study published in Nature Health on June 15, 2026, reveals that new antidepressant prescriptions in England have fallen below pre-pandemic levels. • The research analyzed primary care dispensing data spanning from 2019 to 2024 to track prescribing trends across the country. • This shift is significant as it provides a comprehensive look at how mental health treatment patterns have evolved following the COVID-19 pandemic.

• The Pharmaceutical Journal has released a detailed analysis of the new community pharmacy contract. • The report examines whether the new framework will stabilize medicines funding and evaluates its promises regarding long-term systemic reform. • A key focus is placed on how new national prescribing services will integrate with existing local commissioning structures.